Roivant Sciences(ROIV) - 2026 Q3 - Earnings Call Transcript

Financial Data and Key Metrics Changes - The company reported a non-GAAP net loss of $167 million for the quarter, with R&D expenses at $165 million and G&A expenses at $175 million [30] - The company maintains a strong cash position with $4.5 billion in consolidated cash, providing ample capital to reach profitability and pursue additional opportunities [30] Business Line Data and Key Metrics Changes - The NDA for brepocitinib in dermatomyositis has been submitted, and the phase IIb study for 1402 in D2T-RA has fully enrolled [6][7] - The phase II study for mosliciguat in PH-ILD has also fully enrolled, with top-line data expected in the second half of the year [7][28] Market Data and Key Metrics Changes - The company is targeting a large addressable patient population for brepocitinib, particularly in orphan inflammatory diseases with high unmet needs [25][36] - The company estimates around 40,000 eligible patients for cutaneous sarcoidosis, indicating a significant market opportunity [77] Company Strategy and Development Direction - The company is focused on expanding the development of brepocitinib into additional indications, emphasizing its potential as a first-in-class therapy for sarcoidosis [35][36] - The company plans to leverage insights from the phase II study to inform the design of the phase III trial, aiming for a similar size and endpoint duration [79] Management's Comments on Operating Environment and Future Outlook - Management expressed enthusiasm about the strong phase II data for brepocitinib, highlighting its potential to address significant patient needs in various indications [25][36] - The company anticipates a catalyst-rich period ahead, with multiple NDA and BLA filings expected in the coming years [31] Other Important Information - The jury trial against Moderna is scheduled for March 9, with recent favorable decisions regarding summary judgment [29] - The company is exploring further development opportunities for brepocitinib, including potential expansion into other forms of sarcoidosis [36][84] Q&A Session Summary Question: What are the further development opportunities for brepocitinib? - Management is enthusiastic about further development and is considering additional indications, emphasizing the strong data supporting brepocitinib's efficacy [35] Question: Can you provide more details on the baseline characteristics of the CSAMI numbers? - Management noted that there were some significant differences in baseline characteristics, including disease duration and morphology, which may have influenced the results [42][43] Question: What is the pricing strategy for brepocitinib? - Management has not finalized pricing but indicated it will be positioned as an orphan-priced drug, with considerations based on existing therapies [48][50] Question: What is the expected size and design of the phase III study? - Management indicated that the phase III study would likely be similar in size to the DM trial, with final details to be determined after discussions with the FDA [59][79] Question: What percentage of patients in the Brepo study had organ involvement? - Approximately 60% of patients had pulmonary involvement, and around 30% had other organ involvement, primarily ocular [84]